Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Xortx Therapeutics Inc (XRTX)

Xortx Therapeutics Inc (XRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,856
  • Shares Outstanding, K 1,999
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,160 K
  • 60-Month Beta 0.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.12
Trade XRTX with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.51 +5.37%
on 04/25/24
3.92 -32.53%
on 04/09/24
-1.06 (-28.51%)
since 03/28/24
3-Month
2.20 +20.23%
on 02/14/24
7.00 -62.21%
on 03/07/24
+0.20 (+8.40%)
since 01/29/24
52-Week
1.98 +33.59%
on 12/27/23
7.52 -64.85%
on 10/20/23
-3.12 (-54.12%)
since 04/28/23

Most Recent Stories

More News
XORTX Announces Submission to European Medicines Agency

Scientific Advice from EMA Committee for Medicinal Products for Human Use Requested...

XRTX.VN : 3.600 (-11.55%)
XRTX : 2.64 (-9.73%)
XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial

Clinical Trial Shows Substantially Improved Bioavailiability...

XRTX.VN : 3.600 (-11.55%)
XRTX : 2.64 (-9.73%)
XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)

CALGARY, Alberta, July 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a...

XRTX.VN : 3.600 (-11.55%)
XRTX : 2.64 (-9.73%)
XORTX to Present at BIO International Convention 2022

CALGARY, Alberta, June 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a...

XRTX.VN : 3.600 (-11.55%)
XRTX : 2.64 (-9.73%)
XORTX Welcomes New Member to the Board of Directors and Appoints Chair

CALGARY, Alberta, June 06, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a...

XRTX.VN : 3.600 (-11.55%)
XRTX : 2.64 (-9.73%)
XORTX Receives Small and Medium Enterprise Status for the European Union

CALGARY, Alberta, April 20, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a...

XRTX.VN : 3.600 (-11.55%)
XRTX : 2.64 (-9.73%)
XORTX Receives No Objection Letter from Health Canada

Bridging Pharmacokinetics Study Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program...

XRTX.VN : 3.600 (-11.55%)
XRTX : 2.64 (-9.73%)
XORTX Announces Grant of US Patent

Patent supporting Autosomal Dominant Polycystic Kidney Disease Granted – XRx-008 Program...

XRTX.VN : 3.600 (-11.55%)
XRTX : 2.64 (-9.73%)
XORTX Files IND with US FDA

● Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program IND Filed ● CALGARY, Alberta, March 31, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics...

XRTX.VN : 3.600 (-11.55%)
XRTX : 2.64 (-9.73%)
XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

Compositions and Methods for Enhancing Anti-Viral Therapies...

XRTX.VN : 3.600 (-11.55%)
XRTX : 2.64 (-9.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

XORTX Therapeutics Inc. is a pharmaceutical therapeutics company. It focused on developing therapies to treat progressive kidney disease. XORTX Therapeutics Inc. is based in CALGARY, Alberta.

See More

Key Turning Points

3rd Resistance Point 3.75
2nd Resistance Point 3.50
1st Resistance Point 3.07
Last Price 2.64
1st Support Level 2.39
2nd Support Level 2.13
3rd Support Level 1.71

See More

52-Week High 7.52
Fibonacci 61.8% 5.41
Fibonacci 50% 4.75
Fibonacci 38.2% 4.10
Last Price 2.64
52-Week Low 1.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar